Acute graft versus host disease.

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Acute graft-versus-host disease (GVHD) is a significant complication post-allogeneic hematopoietic stem cell transplant (HSCT).
• It arises from donor immune cell attack on host tissues, triggered by the preparative regimen.
• An estimated 5500 HSCT patients annually develop acute GVHD, with incidence varying by transplant factors.

Purpose of the Study:

• To summarize the clinical presentation, diagnosis, staging, and current treatment strategies for acute GVHD.
• To highlight the need for improved second-line therapies and clinical trials.
• To underscore the management of associated complications and the transition to chronic GVHD.

Main Methods:

• Clinical diagnosis based on organ involvement (skin, liver, GI tract).
• Staging and grading (0-IV) determine severity and prognosis.
• Treatment involves optimizing immunosuppression and methylprednisolone; salvage therapy is considered for non-responders.

Main Results:

• Approximately 35-50% of HSCT recipients develop acute GVHD.
• Methylprednisolone yields a solid response in about 50% of patients.
• About 50% of patients with acute GVHD will develop chronic GVHD manifestations.

Conclusions:

• Acute GVHD requires careful management, with initial treatment focusing on immunosuppression and corticosteroids.
• Lack of standard-of-care for salvage therapy necessitates well-organized clinical trials.
• Effective management of acute GVHD is critical, considering its potential progression to chronic GVHD.